• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Let's Get Real About Johnson & Johnson's Selloff and How to Play the Stock

I find a lot of Reuters' claims hard to believe. Even more difficult to believe is the selloff.
By TIMOTHY COLLINS
Dec 17, 2018 | 11:28 AM EST
Stocks quotes in this article: JNJ

Reuters made a big splash on Friday with its hard-hitting expose on Johnson & Johnson (JNJ) . The accuracy of the report is being called into question by many on Wall Street, along with the company itself, but the damage to the stock price in the short-term is certainly not in question.

Over the weekend, I had the chance to get out to a few neighborhood functions. While talking with folks, I brought up the Johnson & Johnson story several times in the course of different conversations. Not a single person had heard the story except for one person who works in the financial markets. In other words, I'm not sure how widespread this story is resonating outside of traders and investors.

I was certain a scan of social media would find folks screaming for torches and pitchforks, but again, I found very little in my network of friends. I'm getting the notion the only perception problem here may be a Wall Street one. Until we see a Boston Talc Party with consumers dumping baby powder into the sea, I'm not sure we'll see much in the way of consumer abandonment of J&J products.

That doesn't mean financial risk is off the table. J&J is facing a group of 11,700 plaintiffs claiming their product contained asbestos and caused cancer. If this plays out in court, the burden of proof lies with the plaintiffs, which means they will have to do something that has never been done: scientifically show a causal link between baby powder usage and cancer. If we assume the market cap cut (around $40 billion give-or-take the fast market moves), that works out to around $3 million+ per claimant. Again, possible, but not likely.

J&J did just have a jury in California rule it was not liable in a similar case last month. Add in the thousands of tests done not only by the company, but also tests done by the FDA, global regulators, and independent labs.

Reuters claims this goes all back to the 1970s, possibly even the 1950s. If that's true, then that means the level of fraud, conspiracy, and/or incompetence reaches levels never before experienced in human history. I find it hard to believe. Even more difficult to believe is the selloff.

In the bigger picture, JNJ has done nothing more than retrace close to a very long-trending support level that goes back almost four years. I believe that $125 level would be our short-term strong support, although I find JNJ attractive here.

I would approach JNJ with a "buy half" mentality. Buy half a position Monday, then consider adding should it drop into the $105-115 range. Otherwise, simply enjoy a well-timed buy if the stock continues to rise.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Collins had no positions in JNJ.

Action Alerts PLUS, which Cramer manages as a charitable trust, is long JNJ.

TAGS: Fundamental Analysis | Investing | Stocks | Technical Analysis | Healthcare | U.S. Equity | Stock of the Day

More from Stocks

Traders: Keep Your Fingers on the Trigger and Targets on a Bottom

James "Rev Shark" DePorre
Mar 4, 2021 4:39 PM EST

As the correction goes on, here's what to do now.

There's Nothing Pleasant About the Current Action

Timothy Collins
Mar 4, 2021 3:00 PM EST

The next good sized bounce in SPAC names, and maybe ARKK names, might be the last exit off the bagholder highway.

Nike's Charts and Indicators Are Still Bearish

Bruce Kamich
Mar 4, 2021 2:20 PM EST

Avoid the long side.

Listen to Mr. Market, Not Mr. Powell

Jim Collins
Mar 4, 2021 1:56 PM EST

Let's look at bonds, rates and, especially, inflation for a true picture of what's going on, and where to put your money.

Powell Supplies the Bears With Ammunition

James "Rev Shark" DePorre
Mar 4, 2021 1:20 PM EST

Picking good stocks is not going to help you much in this market right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:53 AM EST GARY BERMAN

    Nasdaq Composite: Some Backing and Filling Is Here

    As today is the 4th day of the month, it seems lik...
  • 07:59 AM EST PAUL PRICE

    Fabulous News on United Natural Foods (UNFI)

    The major potential risk factor for , its contrac...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login